Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases
fSCIG 10% effectively prevented ASBIs in pediatric patients with PIDDs, with a favorable safety profile consistent with previous clinical studies.
Authors
- Richard L. Wasserman (ORCID: https://orcid.org/0000-0002-3447-4859)
- Jolán E. Walter (ORCID: https://orcid.org/0000-0002-6192-0703)
- Meagan Shepherd
- Leman Yel (ORCID: https://orcid.org/0000-0001-8357-3186)
- Niraj Patel (ORCID: https://orcid.org/0000-0002-3657-145X)
- Suthida Kankirawatana
- Sharon Russo-Schwarzbaum
- Shumyla Saeed-Khawaja
- Zhaoyang Li (ORCID: https://orcid.org/0000-0003-4625-1107)
- Erin Greco
- Arye Rubinstein
- Barbara McCoy
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- Johns Hopkins University (US)
- Duke University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University Medical Center (US)
- Children's of Alabama (US)
- University of Alabama at Birmingham (US)
- Massachusetts General Hospital (US)
- Johns Hopkins All Children's Hospital (US)
- ENT and Allergy (US)
- Takeda (United States) (US)
- Takeda (Austria) (AT)
- University of South Florida St. Petersburg (US)
- Marshall University (US)
Publication Details
- Journal
- Journal of Clinical Immunology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1007/s10875-025-01862-6
- Citations
- 2
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.59